Darktrace is a global machine learning company for cyber defense. Recognized for its Enterprise Immune System technology, Darktrace uses artificial intelligence systems to identify and respond to in-progress cyber-threats. The company was established in 2013 and maintains main offices in Cambridge and San Francisco, with a total of 24 offices around the world. Investors in the firm include Michael Richard Lynch's Invoke Capital, Talis Capital, Hoxton Ventures, KKR and Summit Partners.
Darktrace was founded in 2013 by a combination of mathematicians from the University of Cambridge and cyber operations experts from various intelligence agencies. Its Enterprise Immune System technology uses unsupervised machine learning to autonomously detect and take action against cyber-threats within all types of networks, including physical, cloud, virtual, IoT, and ICS environments.
Darktrace is backed by several advisors and investors from the technology, business, and cyber security domains. The company's advisory board includes Alan Wade, former CIO of the CIA; Lord Evans of Weardale KCB, former Director-General of the British security service MI5; and Dr. Michael Richard Lynch OBE, founder of Invoke Capital.
The board of directors is chaired by Robert Webb QC, former General Counsel of Rolls Royce and British Airways. Four of seven of the directors previously worked at HP Autonomy, and the company's CEO, Nicole Eagan, was previously HP Autonomy's chief marketing officer.
Since the company's inception in 2013, its technology has been deployed more than 2,500 times across 5 continents. Darktrace now has over 500 employees around the world.
Darktrace's Enterprise Immune System uses unsupervised machine learning and AI algorithms to build a so-called "pattern of life" for every network, device, and user within an organization. It then employs powerful correlation techniques to classify and cross-reference these models, establishing a highly accurate understanding of 'normal activity' within that particular environment.